| Objective: To observe the clinical effect of Ganlong capsule combined with nucleoside(acid)analogues in treating chronic hepatitis B patients with Steatosis syndrome(stagnation of liver-qi and deficiency of the spleen type),to evaluate the clinical effectiveness and security of using Ganlong capsule in combination with nucleoside analogues to treat this condition.to offer a fresh,secure way for clinically diagnosing and treating CHB with NAFLD.Methods: Outpatients and inpatients diagnosed with CHB and NAFLD(hepatodepressed and spleen deficiency)in the Department of Infectious Diseases and Hepatology of the First People’s Hospital of Yunnan Province from September 1,2022 to December 31,2022 were collected,and the study was divided into four groups of 36 people in each group(Indicated by(1)(2)(3)(4))with an observation period of 24 weeks using a nonrandomized method.By comparing and analyzing the changes before and after treatment of efficacy indexes(TCM syndrome score,ultrasound liver fat degree,liver transient elastography of liver,laboratory indicators(AST,ALT,CHOL,TG))and safety indicators(three conventional,electrocardiogram)in patients with CHB and NAFLD,SPSS26.0statistical analysis software was used for data processing to objectively evaluate the efficacy and safety of the four groups.Results:1.TCM symptoms: There were significant differences in the scores of abdominal pain,abdominal distention,loose stool,poor appetite,and fatigue before and after treatment in the(3)and(4)groups(P<0.01)),and there were significant differences in the scores of abdominal distension,anorexia,and fatigue before and after treatment in group(1)and(2)(P<0.01),as well,pain and loose stool were differences in group(2)(P<0.05).The scores of TCM syndromes in the(4)groups were significantly higher than those in treatment group(1)((P<0.01)for the five TCM symptoms of abdominal pain,abdominal distention,loose stools,poor appetite,and fatigue.There were also significant differences between the(4)groups((P<0.01),the first four TCM symptoms and the(3)groups((P<0.05),the five TCM symptoms and the(4)groups((P<0.05),and the symptoms of abdominal pain and fat.2.Liver function:2.1 The levels of alanine aminotransferase(ALT)and aspartate aminotransferase(AST)were significantly different after 12 weeks of treatment in the(3)group and(4)group(P<0.01),and after treatment,the difference between the AST and ALT groups in the four groups was significantly different(P<0.01),and the level difference(P<0.05)in the(1)(3),(2)(4),and(3)(4)groups was significantly different(P<0.01)in the ALT,(1)(4).The level difference between groups(3)and(4)was statistically significant(P<0.05),as was the level difference between groups(2)and(4).2.2 The difference in ALT and AST levels in the(2),(3),and(4)groups after 24 weeks of treatment was significant(P<0.01),and after treatment,the differences between the AST and ALT groups in the 4 groups were significant(P<0.01),and in the comparison of AST,the differences between(P<0.01),(1)(3),(1)(4)and(2)(4),at the same time,(1)(3),(1)(4),(2)(4)and(3)(4)groups were significant(P<0.05)in terms of ALT.3.Blood lipids: Following treatment,there were significant differences in triglycerides(TG),(2)and(3)within the groups(P<0.05),(4)within the groups(P<0.01),and(3)and(4)between the four groups in terms of CHOL(P<0.01),(2)within the groups(P<0.05).In the comparison of pairs,In terms of CHOL,there were significant differences in(1)(4),(2)(4),(3)(4)groups(P<0.01)and differences in(1)(3)groups(P<0.05),In terms of TG,the differences in(P<0.01)and(3)(4)were statistically significant(P<0.05)as were the differences in(2)(4),(1)(4),and(1)(3).4.Ultrasound: After receiving treatment for 24 weeks,groups(2),(3),and(4)showed significantly different results(P<0.01).Following treatment,there were significant changes across the four groups(P<0.01),as well as(1)(4),(1)(4),and(2)(4)groups(P<0.01).5.Liver transient elastography: After 24 weeks of treatment,there were significant differences in liver stiffness between the(2)groups and the(3)groups(P<0.05),as well as significant differences among the(4)groups(P<0.01)according to liver transient elastography.The(3)groups showed a significant difference(P<0.05),and the(2)groups and the(4)groups showed a significant difference(P<0.01).There were significant variations in liver stiffness and hepatic fat attenuation between groups(1)(4),(1)(4),and(2)(4)after therapy(P<0.01),and there was a significant difference between the four groups overall.6.After 24 weeks of treatment,the total effective rate for(4)groups(94.29%)was higher than the total effective rate for(2)groups(30.30%),and the total effective rate for(1)group(21.21%)was higher than the total effective rate for(3)groups(6.06%).Significant differences between the(1)(4)and(3)(4)groups(P<0.05))and the(2)(4)groups(P<0.01)were discovered.,respectively.There were significant differences in the overall effectiveness across the(4)groups(80.00%),the(2)groups(45.45%),the(3)groups(33.33%),and the(1)group(12.12%),with a P value of 0.01.The(1)(2),(1)(4),(2)(4),and(3)(4)groups(P<0.01),as well as(1)(3)groups(P<0.05),all showed significant differences.7.Safety index: There were no adverse events during treatment in the four groups,indicating that the drug in this study had a good safety profile.Conclusion:1.Nucleoside(acid)analogues plus hepatodragon capsules combined with controlled exercise diet group had excellent efficacy in the treatment of CHB combined with NAFLD(liver depression and spleen deficiency)in this study.2.All four groups could reduce the score of TCM symptoms in patients,and nucleoside(acid)analogues plus hepatosaurus capsules combined with controlled exercise diet group improved the efficacy best.3.Nucleoside(acid)analogues combined with control exercise diet group,nucleoside(acid)analogues plus hepatodragon capsule group,nucleoside(acid)analogues plus hepatodragon capsules combined with control exercise diet group can improve patients’ laboratory indicators(AST,ALT,CHOL,TG),liver stiffness,liver fat attenuation,ultrasound liver fat attenuation,etc.,and nucleoside(acid)analogues plus hepatodragon capsules combined with control exercise diet group improved the best effect.4.There was no significant improvement in laboratory indicators(AST,ALT,CHOL,TG),liver stiffness,liver fat attenuation,ultrasound liver fat attenuation and other aspects in the nucleoside(acid)analogue group.5.There were no adverse reaction events in the four groups,which proves that in this study,nucleoside(acid)analogues plus hepatodragon capsules combined with control exercise diet has a certain safety. |
PDF Full Text Request